Clinical pharmacokinetics of bevacizumab in patients with solid tumors

被引:304
作者
Lu, Jian-Feng [1 ]
Bruno, Rene [1 ]
Eppler, Steve [1 ]
Novotny, William [2 ]
Lum, Bert [1 ]
Gaudreault, Jacques [1 ]
机构
[1] Genentech Inc, Dept Pharmacokinet & Pharmacodynam Sci, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Clin Sci, San Francisco, CA 94080 USA
关键词
population pharmacokinetics; bevacizumab; monoclonal antibody; covariate effect; dosing schedule;
D O I
10.1007/s00280-007-0664-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective To characterize the population pharmacokinetics of bevacizumab and the influence of demographic factors, disease severity, and concomitantly used chemotherapy agents on it's pharmacokinetic behavior. Patients and methods Data from eight clinical trials with bevacizumab administered by intravenous infusion were included. A total of 4,629 bevacizumab concentrations from 491 patients with solid tumors, who received bevacizumab doses ranging from 1 to 20 mg/kg at a dosing frequency ranging from weekly to every 3 weeks, were analyzed using a nonlinear mixed-effects modeling approach (NONMEM). Results The best structural model was a two-compartment model with first-order elimination. In the final model, estimated clearance (CL) and central compartment volume of distribution (V-c) were 0.207 L/day and 2.39 L for a typical female. The terminal half-life estimate was similar to 20 days for both men and women. Body weight and gender were the most significant covariates to explain interpatient variability for CL and V-c. Clearance was 26% faster in men than in women. Patients with low serum albumin and high serum alkaline phosphatase had 19 and 23% faster CL, respectively, than a typical patient. Consistent with the long elimination half life, simulations showed that similar steady-state exposures can be maintained when the weekly mg/kg dose rate is maintained, therefore allowing administration of bevacizumab to coincide with the frequency of administration of the cytotoxic agents. Conclusion The PK parameters were consistent with those of other IgG molecules. The results support dosing bevacizumab on a once every 2 weeks or once every 3 weeks dosing schedule on a mg/kg basis.
引用
收藏
页码:779 / 786
页数:8
相关论文
共 20 条
[1]  
BEAL SL, 1992, NONMEM USERS GUIDE
[2]   Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer [J].
Bruno, R ;
Washington, CB ;
Lu, JF ;
Lieberman, G ;
Banken, L ;
Klein, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (04) :361-369
[3]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[4]  
*GEN INC, 2004, AVASTIN PACK INS
[5]  
*GEN INC, 2003, AV BIOL LIC APPL BLA
[6]  
GIANTONIO BJ, 2005, J CLIN ONCOL, V23, P2
[7]   Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: Some inferences [J].
Gobburu, JVS ;
Lawrence, J .
PHARMACEUTICAL RESEARCH, 2002, 19 (01) :92-98
[8]   Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer [J].
Gordon, MS ;
Margolin, K ;
Talpaz, M ;
Sledge, GW ;
Holmgren, E ;
Benjamin, R ;
Stalter, S ;
Shak, S ;
Adelman, DC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :843-850
[9]  
HSEI VC, 2001, P AM SOC CLIN ONCOL, V20
[10]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342